FDA delays Botox alternative Reloxin

FDA delays Botox alternative Reloxin
The US Food and Drug Administration (FDA) has delayed approving Botox alternative Reloxin while it discusses labelling and risk mitigation with the manufacturers of the drug, Medicis Pharmaceutical Corp and Ipsen SA. 

The FDA is expected to delay Reloxin to market until later this year, questioning how the manufacturers plan to track the use of the product to minimise potential risks.

Reloxin will likely be priced at 15% lower than Botox, leading analysts to predict that annual sales of the product will reach $160m by 2012.


16 April 2009

More Botox and facial rejuvenation stories

Botox fears overblown, says expert »
Botox not feeling the recession pinch »
DIY Botox may be doing you an injury »
Botox competitor approved by the FDA »
Credit crunch Botox can be bad for your health »
FDA delays Botox alternative Reloxin »

RSS News Feeds Subscribe to the latest cosmetic dentistry news via the RSS feed

Other news for: Nov - 2007, Dec - 2007, Jan - 2008, Feb - 2008, Mar - 2008, Apr - 2008, May - 2008, Jun - 2008, Jul - 2008, Aug - 2008, Sep - 2008, Oct - 2008, Nov - 2008, Dec - 2008, Jan - 2009, Feb - 2009, Mar - 2009, Apr - 2009, May - 2009, Jun - 2009, Jul - 2009, Aug - 2009, Sep - 2009, Oct - 2009, Nov - 2009,

Gallery of Smiles

View Smile Gallery